Activating BRAF mutations are present in approximately 50% of cutaneous melanomas, and eligible patients receiving a combined BRAF/MEK-inhibitor therapy have a response rate of approximately 70%9,10 though these responses are not as durable as the ones observed by immunotherapy. This evidence concerns the gene MAP2K7 and cutaneous melanoma.